Literature DB >> 11186257

Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state.

S K Ballas1, M J Marcolina.   

Abstract

We have studied 26 patients with sickle cell anemia to determine the factors that affect red blood cell (RBC) survival and other parameters of erythropoietic activity in the steady state. Determinants of erythropoietic activity included RBC survival by the 51Cr method, RBC production/destruction rate, alpha genotype, beta(s) haplotype, plasma 59Fe clearance, plasma iron turnover, erythron transferrin uptake), RBC Fe utilization, reticulocyte count, and erythropoietin levels. The alpha genotype was the most significant determinant of RBC survival followed, to a lesser extent, by the beta(s) haplotype. Hb F showed no correlation with RBC survival due to patient selection bias - the patients studied had comparable Hb F levels to start with. Other determinants of erythropoietic activity (hemoglobin level, mean corpuscular volume, reticulocyte count, RBC mass, RBC production/destruction rate, and erythropoietin level) were most likely secondary determinants associated with the alpha genotype, and not independent determinants in themselves. The data suggest that the alpha genotype and, and to a lesser extent, the beta(s) haplotype, might be determinants of the severity of the anemia of sickle cell disease, and should be considered in genetic counseling and patient selection for aggressive therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186257     DOI: 10.3109/03630260008993134

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  10 in total

1.  Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.

Authors:  Jane A Little; Vicki R McGowan; Gregory J Kato; Kristine S Partovi; Jordan J Feld; Irina Maric; Sabrina Martyr; James G Taylor; Roberto F Machado; Theo Heller; Oswaldo Castro; Mark T Gladwin
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

2.  The CT Prevalence of Arrested Pneumatization of the Sphenoid Sinus in Patients with Sickle Cell Disease.

Authors:  A V Prabhu; B F Branstetter
Journal:  AJNR Am J Neuroradiol       Date:  2016-05-05       Impact factor: 3.825

3.  Hemolysis-associated priapism in sickle cell disease.

Authors:  Vikki G Nolan; Diego F Wyszynski; Lindsay A Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

4.  Integration of biology, mathematics and computing in the classroom through the creation and repeated use of transdisciplinary modules.

Authors:  Mentewab Ayalew; Derrick Hylton; Jeticia Sistrunk; James Melton; Kiandra Johnson; Eberhard Voit
Journal:  PRIMUS (Terre Ht)       Date:  2021-01-13

5.  Placental growth factor attenuates suppression of erythroid colony formation by interferon.

Authors:  Gail Dallalio; Robert T Means
Journal:  Transl Res       Date:  2008-10-29       Impact factor: 7.012

6.  Polymorphisms of the receptor for advanced glycation end products as vasculopathy predictor in sickle cell disease.

Authors:  Nesma Ahmed Safwat; Mai Mohamed ELkhamisy; Soha Ezz AlArab Abdel-Wahab; Mohamed Tarif Hamza; Noha Hussein Boshnak; Mahmoud Adel Kenny
Journal:  Pediatr Res       Date:  2020-06-16       Impact factor: 3.756

7.  Insights into age- and sickle-cell-disease-interaction using principal components analysis.

Authors:  Mamta Sharma; Manju R Mamtani; Manik Amin; Tushar P Thakre; Smita Sharma; Amit Amin; Hemant Kulkarni
Journal:  BMC Blood Disord       Date:  2006-09-04

8.  CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia.

Authors:  Dorie A Makropoulos; Ram Achuthanandam; Justin Avery; Krista Wilson; Kerry Brosnan; Andrew Miller; Thomas Nesspor; Denise Chroscinski; Mindi Walker; Devon Egenolf; ChiChi Huang; Peter J Bugelski
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

9.  Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia.

Authors:  Clarisse Lopes de Castro Lobo; Emilia Matos do Nascimento; Renato Abelha; Ana Maria Mach Queiroz; Philippe Connes; Gilberto Perez Cardoso; Samir K Ballas
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

Review 10.  Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration.

Authors:  Shahida A Khan; Ghazi Damanhouri; Ashraf Ali; Sarah A Khan; Aziz Khan; Ahmed Bakillah; Samy Marouf; Ghazi Al Harbi; Saeed H Halawani; Ahmad Makki
Journal:  Nutr Metab (Lond)       Date:  2016-08-08       Impact factor: 4.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.